Thomas G. Wiggans
Known title: DirectorCIK: 0001208907
Thomas G. Wiggans's purchase track record
How the stock did after each of Thomas G. Wiggans's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since November 16, 2023
Stock higher 6 months later
67%
3 months: 67%
Median 6-month return
+268.9%
3 months: +193.3%
Beat the S&P 500
67%
median +252.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/22/2025 | JSPR | $100K | -24.8% | -53.1% | -1.7% |
| 11/28/2023 | JSPR | $6K | +223.5% | +268.9% | +16.5% |
| 11/16/2023 | JSPR | $25K | +193.3% | +273.3% | +17.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| JSPR | ▲ Buy | Open Market | 41,000 | $100K | 9/22/2025 | View on chart |
| JSPR | ▲ Buy | Open Market | 10,000 | $6K | 11/28/2023 | View on chart |
| JSPR | ▲ Buy | Open Market | 10,000 | $6K | 11/21/2023 | View on chart |
| JSPR | ▲ Buy | Open Market | 10,000 | $6K | 11/20/2023 | View on chart |
| JSPR | ▲ Buy | Open Market | 10,000 | $6K | 11/17/2023 | View on chart |
| JSPR | ▲ Buy | Open Market | 10,000 | $6K | 11/16/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.